Vericel (VCEL) Depreciation & Amortization (CF) (2010 - 2026)
Vericel's (VCEL) quarterly Depreciation & Amortization (CF) came in at $3.3 million in Q1 2026, up 21.63% year-on-year from $2.7 million in Q1 2025, and up 5.8% quarter-over-quarter from $3.1 million in Q4 2025.
Vericel (VCEL) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Vericel has disclosed Depreciation & Amortization (CF) across 17 years of filings, most recently posting $3.3 million for Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $3.3 million, up 21.63% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.1 million (up 77.99% YoY), and the FY2025 annual result was $11.5 million, up 109.74% from the prior year.
- Depreciation & Amortization (CF) came in at $3.3 million for Q1 2026 at Vericel, up from $3.1 million in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $3.3 million in Q1 2026 to a low of $873000.0 in Q1 2022.
- The 5-year median for Depreciation & Amortization (CF) is $1.3 million (2024), against an average of $1.7 million.
- Across the five-year window, Depreciation & Amortization (CF) climbed 6.45% in 2023 and surged 122.02% in 2025, its largest moves.
- Vericel's Depreciation & Amortization (CF) stood at $1.0 million in 2022, then rose by 10.59% to $1.1 million in 2023, then advanced by 28.55% to $1.5 million in 2024, then soared by 109.07% to $3.1 million in 2025, then grew by 5.8% to $3.3 million in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $3.3 million (Q1 2026), $3.1 million (Q4 2025), and $2.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Vericel | 2.04 Bn | 1.90 Bn | 49.27 Mn | 3.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.27 Mn |
| Mar 31, 2026 | 3.27 Mn |
| Dec 31, 2025 | 3.09 Mn |
| Dec 31, 2025 | 3.09 Mn |
| Sep 30, 2025 | 2.94 Mn |
| Sep 30, 2025 | 2.94 Mn |
| Jun 30, 2025 | 2.83 Mn |
| Jun 30, 2025 | 2.83 Mn |
| Mar 31, 2025 | 2.69 Mn |
| Mar 31, 2025 | 2.69 Mn |
| Dec 31, 2024 | 1.48 Mn |
| Dec 31, 2024 | 1.48 Mn |
| Sep 30, 2024 | 1.33 Mn |
| Sep 30, 2024 | 1.33 Mn |
| Jun 30, 2024 | 1.32 Mn |
| Jun 30, 2024 | 1.32 Mn |
| Mar 31, 2024 | 1.38 Mn |
| Mar 31, 2024 | 1.38 Mn |
| Dec 31, 2023 | 1.15 Mn |
| Dec 31, 2023 | 1.15 Mn |